We identify the existence of a molecular mechanism shielding the tumor from immune attack regulated by the IL-6/STAT3/SMG1 axis that prevents antitumor immune responses: a new immunoediting process to silence potent neoantigens by immune intrinsic pathways that affect the activity of NMD. The gene discussed is STAT3; the disease is neoplasm.